Adjuvant Chemotherapy in Patients with Low-Risk Epithelial Ovarian Cancer: A Taiwanese Cohort Study

Background: Whether or not patients with stage I epithelial ovarian cancer (EOC) benefit from postoperative chemotherapy in the Asian population remains unclear. This retrospective cohort study was aimed at investigating the use of adjuvant chemotherapy in clinical practice to treat patients with ea...

Full description

Bibliographic Details
Published in:	Journal of Cancer Research and Practice
Main Authors:	Yuan-Ting C. Lo, Hsiu-Ying Ku, Cheng-Shyong Chang, Hui-Ju Ch’ang, Chih-Ming Ho, Tsang-Wu Liu, Shih-Min Lin
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2023-04-01
Subjects:	adjuvant chemotherapy clinical practice epithelial ovarian cancer low risk survival
Online Access:	https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00003

Similar Items

Epithelial ovarian cancer: Review article
by: Suchetha Sambasivan
Published: (2022-01-01)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
by: Xingyu Liu, et al.
Published: (2023-06-01)

Association between time to adjuvant chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
by: Sergei Iugai, et al.
Published: (2025-04-01)

Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study
by: L. Steventon, et al.
Published: (2025-06-01)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage III C and IV epithelial ovarian cancer
by: Forde GK, et al.
Published: (2016-08-01)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
by: Lin H, et al.
Published: (2021-07-01)

Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia
by: Rushi Shah, et al.
Published: (2023-10-01)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer [Corrigendum]
by: Lin H, et al.
Published: (2021-08-01)

Prognostic factors for pure ovarian immature teratoma and the role of adjuvant chemotherapy in stage I diseases
by: Sijian Li, et al.
Published: (2023-12-01)

The impact of multiple neoadjuvant chemotherapy cycles in patients with advanced epithelial ovarian cancer: A single center experience
by: Wala Mehros, et al.
Published: (2025-01-01)

Lymphocyte-to-monocyte ratio after primary surgery is an independent prognostic factor for patients with epithelial ovarian cancer: A propensity score matching analysis
by: Qian Hu, et al.
Published: (2023-03-01)

Clinical efficacy analysis of chemotherapy of isolated neck lymphatic metastasis in advanced epithelial ovarian cancer
by: Hong Liu, et al.
Published: (2025-05-01)

Prognostic Factors for Different Treatment Regimens in Advanced Epithelial Ovarian Cancer
by: LIU Chuanzhong, et al.
Published: (2018-10-01)

Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer
by: Myeong-Seon Kim, et al.
Published: (2022-09-01)

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
by: Yan Gao, et al.
Published: (2019-09-01)

Adipose tissue loss during neoadjuvant chemotherapy: a key prognostic factor in advanced epithelial ovarian cancer
by: Wassim Benouali, et al.
Published: (2025-03-01)

Therapy for Recurrent High-Grade Epithelial Ovarian Cancer—The Current Status and Future Trends
by: Vallathol Dilip Harindran, et al.
Published: (2024-04-01)

Treatment Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Propensity Score Overlap Weighting Analysis of a Multicenter Taiwanese Cohort
by: Yi-Ju Chou, et al.
Published: (2025-11-01)

Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125
by: Szu-Ting Yang, et al.
Published: (2023-11-01)

Feasibility and ability of laparoscopy to predict respectability in ovarian cancer: A cohort study
by: Mohammed Abdelrahman, et al.
Published: (2023-01-01)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
by: Huan Wang, et al.
Published: (2022-06-01)

The dual edges of neoadjuvant chemotherapy in advanced epithelial ovarian cancer: Therapeutic potential and clinical dilemmas
by: Li Jia, et al.
Published: (2024-12-01)

ADJUVANT CHEMOTHERAPY AFTER RECTAL CANCER CHEMORADIOTHERAPY
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01)

Effect of different treatment modalities on the prognosis of stage IV epithelial ovarian cancer: analysis of the SEER database
by: Shuyuan Zhang, et al.
Published: (2024-06-01)

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
by: Wei-Chun Chen, et al.
Published: (2022-10-01)

The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
by: Hongyuan Gu, et al.
Published: (2020-06-01)

Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study
by: Guangming Cao, et al.
Published: (2023-03-01)

Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy
by: R. Kleef, et al.
Published: (2012-05-01)

Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy
by: Mao‐Chih Hsieh, et al.
Published: (2018-06-01)

Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma
by: Ho Chih-Ming, et al.
Published: (2012-02-01)

CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study
by: Mengge He, et al.
Published: (2025-07-01)

The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience
by: Ching-Fen Hu, et al.
Published: (2015-02-01)

Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data
by: Shalkar Adambekov, et al.
Published: (2020-10-01)

Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)
by: E. V. Sibirskaya, et al.
Published: (2024-05-01)

The impact of delayed adjuvant chemotherapy on survival in gastric cancer patients with and without preoperative chemotherapy
by: Masataka Shimonosono, et al.
Published: (2025-07-01)

Adjuvant chemotherapy for gastric cancer
by: I. P. Kolesnyk, et al.
Published: (2015-12-01)

The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer
by: Yuchong Yang, et al.
Published: (2023-05-01)

Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer
by: Vanita Noronha, et al.
Published: (2012-01-01)

Hyperthermic intraperitoneal chemotherapy after upfront cytoreductive surgery for stage III epithelial ovarian cancer: Follow‐up of long‐term survival
by: Ziying Lei, et al.
Published: (2025-05-01)